-
1
-
-
78651330430
-
COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
-
S. A. Forbes, N. Bindal, S. Bamford, C. Cole, C. Y. Kok, D. Beare, M. Jia, R. Shepherd, K. Leung, A. Menzies, J. W. Teague, P. J. Campbell, M. R. Stratton, P. A. Futreal, COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
-
(2011)
Nucleic Acids Res.
, vol.39
-
-
Forbes, S.A.1
Bindal, N.2
Bamford, S.3
Cole, C.4
Kok, C.Y.5
Beare, D.6
Jia, M.7
Shepherd, R.8
Leung, K.9
Menzies, A.10
Teague, J.W.11
Campbell, P.J.12
Stratton, M.R.13
Futreal, P.A.14
-
2
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
C. L. Vogel, M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, S. Shak, S. J. Stewart, M. Press, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
Gutheil, J.C.4
Harris, L.N.5
Fehrenbacher, L.6
Slamon, D.J.7
Murphy, M.8
Novotny, W.F.9
Burchmore, M.10
Shak, S.11
Stewart, S.J.12
Press, M.13
-
3
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, D. J. Slamon, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
Wolter, J.M.7
Paton, V.8
Shak, S.9
Lieberman, G.10
Slamon, D.J.11
-
4
-
-
77956513286
-
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
-
G. Bollag, P. Hirth, J. Tsai, J. Zhang, P. N. Ibrahim, H. Cho, W. Spevak, C. Zhang, Y. Zhang, G. Habets, E. A. Burton, B. Wong, G. Tsang, B. L. West, B. Powell, R. Shellooe, A. Marimuthu, H. Nguyen, K. Y. Zhang, D. R. Artis, J. Schlessinger, F. Su, B. Higgins, R. Iyer, K. D'Andrea, A. Koehler, M. Stumm, P. S. Lin, R. J. Lee, J. Grippo, I. Puzanov, K. B. Kim, A. Ribas, G. A. McArthur, J. A. Sosman, P. B. Chapman, K. T. Flaherty, X. Xu, K. L. Nathanson, K. Nolop, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
-
(2010)
Nature
, vol.467
, pp. 596-599
-
-
Bollag, G.1
Hirth, P.2
Tsai, J.3
Zhang, J.4
Ibrahim, P.N.5
Cho, H.6
Spevak, W.7
Zhang, C.8
Zhang, Y.9
Habets, G.10
Burton, E.A.11
Wong, B.12
Tsang, G.13
West, B.L.14
Powell, B.15
Shellooe, R.16
Marimuthu, A.17
Nguyen, H.18
Zhang, K.Y.19
Artis, D.R.20
Schlessinger, J.21
Su, F.22
Higgins, B.23
Iyer, R.24
D'Andrea, K.25
Koehler, A.26
Stumm, M.27
Lin, P.S.28
Lee, R.J.29
Grippo, J.30
Puzanov, I.31
Kim, K.B.32
Ribas, A.33
McArthur, G.A.34
Sosman, J.A.35
Chapman, P.B.36
Flaherty, K.T.37
Xu, X.38
Nathanson, K.L.39
Nolop, K.40
more..
-
5
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
K. T. Flaherty, I. Puzanov, K. B. Kim, A. Ribas, G. A. McArthur, J. A. Sosman, P. J. O'Dwyer, R. J. Lee, J. F. Grippo, K. Nolop, P. B. Chapman, Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
Ribas, A.4
McArthur, G.A.5
Sosman, J.A.6
O'Dwyer, P.J.7
Lee, R.J.8
Grippo, J.F.9
Nolop, K.10
Chapman, P.B.11
-
6
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)
-
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Y. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. P. Dong, J. Baselga, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 21, 2237-2246 (2003).
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
Tamura, T.4
Nakagawa, K.5
Douillard, J.Y.6
Nishiwaki, Y.7
Vansteenkiste, J.8
Kudoh, S.9
Rischin, D.10
Eek, R.11
Horai, T.12
Noda, K.13
Takata, I.14
Smit, E.15
Averbuch, S.16
Macleod, A.17
Feyereislova, A.18
Dong, R.P.19
Baselga, J.20
more..
-
7
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
-
M. G. Kris, R. B. Natale, R. S. Herbst, T. J. Lynch Jr., D. Prager, C. P. Belani, J. H. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, K. S. Albain, D. Cella, M. K. Wolf, S. D. Averbuch, J. J. Ochs, A. C. Kay, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290, 2149-2158 (2003).
-
(2003)
JAMA
, vol.290
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
Lynch Jr., T.J.4
Prager, D.5
Belani, C.P.6
Schiller, J.H.7
Kelly, K.8
Spiridonidis, H.9
Sandler, A.10
Albain, K.S.11
Cella, D.12
Wolf, M.K.13
Averbuch, S.D.14
Ochs, J.J.15
Kay, A.C.16
-
8
-
-
0029947186
-
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
-
B. J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, N. B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
-
(1996)
Nat. Med.
, vol.2
, pp. 561-566
-
-
Druker, B.J.1
Tamura, S.2
Buchdunger, E.3
Ohno, S.4
Segal, G.M.5
Fanning, S.6
Zimmermann, J.7
Lydon, N.B.8
-
9
-
-
84885706147
-
-
accessed 28 August 2013
-
National Cancer Institute, http://www.cancer.gov/ [accessed 28 August 2013].
-
-
-
-
10
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
T. Herceptin Adjuvant Trial Study
-
M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. H. Barrios, G. Steger, C. S. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. M. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. S. Dolci, R. D. Gelber; T. Herceptin Adjuvant Trial Study, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
Gianni, L.7
Baselga, J.8
Bell, R.9
Jackisch, C.10
Cameron, D.11
Dowsett, M.12
Barrios, C.H.13
Steger, G.14
Huang, C.S.15
Andersson, M.16
Inbar, M.17
Lichinitser, M.18
Láng, I.19
Nitz, U.20
Iwata, H.21
Thomssen, C.22
Lohrisch, C.23
Suter, T.M.24
Rüschoff, J.25
Suto, T.26
Greatorex, V.27
Ward, C.28
Straehle, C.29
McFadden, E.30
Dolci, M.S.31
Gelber, R.D.32
more..
-
11
-
-
33845914783
-
2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial
-
HERA Study Team
-
I. Smith, M. Procter, R. D. Gelber, S. Guillaume, A. Feyereislova, M. Dowsett, A. Goldhirsch, M. Untch, G. Mariani, J. Baselga, M. Kaufmann, D. Cameron, R. Bell, J. Bergh, R. Coleman, A. Wardley, N. Harbeck, R. I. Lopez, P. Mallmann, K. Gelmon, N. Wilcken, E. Wist, P. Sánchez Rovira, M. J. Piccart-Gebhart; HERA Study Team, 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369, 29-36 (2007).
-
(2007)
Lancet
, vol.369
, pp. 29-36
-
-
Smith, I.1
Procter, M.2
Gelber, R.D.3
Guillaume, S.4
Feyereislova, A.5
Dowsett, M.6
Goldhirsch, A.7
Untch, M.8
Mariani, G.9
Baselga, J.10
Kaufmann, M.11
Cameron, D.12
Bell, R.13
Bergh, J.14
Coleman, R.15
Wardley, A.16
Harbeck, N.17
Lopez, R.I.18
Mallmann, P.19
Gelmon, K.20
Wilcken, N.21
Wist, E.22
Sánchez Rovira, P.23
Piccart-Gebhart, M.J.24
more..
-
12
-
-
77949903478
-
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
-
J. Baselga, K. A. Gelmon, S. Verma, A. Wardley, P. Conte, D. Miles, G. Bianchi, J. Cortes, V. A. McNally, G. A. Ross, P. Fumoleau, L. Gianni, Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28, 1138-1144 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1138-1144
-
-
Baselga, J.1
Gelmon, K.A.2
Verma, S.3
Wardley, A.4
Conte, P.5
Miles, D.6
Bianchi, G.7
Cortes, J.8
McNally, V.A.9
Ross, G.A.10
Fumoleau, P.11
Gianni, L.12
-
13
-
-
84855297353
-
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial
-
L. Gianni, T. Pienkowski, Y. M. Im, L. Roman, L. M. Tseng, M. C. Liu, A. Lluch, E. Staroslawska, J. de la Haba-Rodriguez, S. A. Im, J. L. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. Bianchi, T. Szado, J. Ratnayake, G. Ross, P. Valagussa, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25-32 (2012).
-
(2012)
Lancet Oncol.
, vol.13
, pp. 25-32
-
-
Gianni, L.1
Pienkowski, T.2
Im, Y.M.3
Roman, L.4
Tseng, L.M.5
Liu, M.C.6
Lluch, A.7
Staroslawska, E.8
De La Haba-Rodriguez, J.9
Im, S.A.10
Pedrini, J.L.11
Poirier, B.12
Morandi, P.13
Semiglazov, V.14
Srimuninnimit, V.15
Bianchi, G.16
Szado, T.17
Ratnayake, J.18
Ross, G.19
Valagussa, P.20
more..
-
14
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365, 1687-1717 (2005).
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
15
-
-
33645459056
-
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93
-
International Breast Cancer Study Group
-
International Breast Cancer Study Group, M. Colleoni, S. Gelber, A. Goldhirsch, S. Aebi, M. Castiglione-Gertsch, K. N. Price, A. S. Coates, R. D. Gelber, Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J. Clin. Oncol. 24, 1332-1341 (2006).
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 1332-1341
-
-
Colleoni, M.1
Gelber, S.2
Goldhirsch, A.3
Aebi, S.4
Castiglione-Gertsch, M.5
Price, K.N.6
Coates, A.S.7
Gelber, R.D.8
-
16
-
-
41649102048
-
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
-
C. Liedtke, C. Mazouni, K. R. Hess, F. André, A. Tordai, J. A. Mejia, W. F. Symmans, A. M. Gonzalez-Angulo, B. Hennessy, M. Green, M. Cristofanilli, G. N. Hortobagyi, L. Pusztai, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275-1281 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 1275-1281
-
-
Liedtke, C.1
Mazouni, C.2
Hess, K.R.3
André, F.4
Tordai, A.5
Mejia, J.A.6
Symmans, W.F.7
Gonzalez-Angulo, A.M.8
Hennessy, B.9
Green, M.10
Cristofanilli, M.11
Hortobagyi, G.N.12
Pusztai, L.13
-
17
-
-
79958711331
-
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
-
M. Bernsdorf, C. Ingvar, L. Jörgensen, M. K. Tuxen, E. H. Jakobsen, A. Saetersdal, M. L. Kimper-Karl, N. Kroman, E. Balslev, B. Ejlertsen, Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res. Treat. 126, 463-470 (2011).
-
(2011)
Breast Cancer Res. Treat.
, vol.126
, pp. 463-470
-
-
Bernsdorf, M.1
Ingvar, C.2
Jörgensen, L.3
Tuxen, M.K.4
Jakobsen, E.H.5
Saetersdal, A.6
Kimper-Karl, M.L.7
Kroman, N.8
Balslev, E.9
Ejlertsen, B.10
-
18
-
-
84864101306
-
TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
-
L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, E. P. Winer, TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J. Clin. Oncol. 30, 2615-2623 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 2615-2623
-
-
Carey, L.A.1
Rugo, H.S.2
Marcom, P.K.3
Mayer, E.L.4
Esteva, F.J.5
Ma, C.X.6
Liu, M.C.7
Storniolo, A.M.8
Rimawi, M.F.9
Forero-Torres, A.10
Wolff, A.C.11
Hobday, T.J.12
Ivanova, A.13
Chiu, W.K.14
Ferraro, M.15
Burrows, E.16
Bernard, P.S.17
Hoadley, K.A.18
Perou, C.M.19
Winer, E.P.20
more..
-
19
-
-
33845191779
-
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
-
K. Chin, S. DeVries, J. Fridlyand, P. T. Spellman, R. Roydasgupta, W.-L. Kuo, A. Lapuk, R. M. Neve, Z. Qian, T. Ryder, F. Chen, H. Feiler, T. Tokuyasu, C. Kingsley, S. Dairkee, Z. Meng, K. Chew, D. Pinkel, A. Jain, B. M. Ljung, L. Esserman, D. G. Albertson, F. M. Waldman, J. W. Gray, Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10, 529-541 (2006).
-
(2006)
Cancer Cell
, vol.10
, pp. 529-541
-
-
Chin, K.1
DeVries, S.2
Fridlyand, J.3
Spellman, P.T.4
Roydasgupta, R.5
Kuo, W.-L.6
Lapuk, A.7
Neve, R.M.8
Qian, Z.9
Ryder, T.10
Chen, F.11
Feiler, H.12
Tokuyasu, T.13
Kingsley, C.14
Dairkee, S.15
Meng, Z.16
Chew, K.17
Pinkel, D.18
Jain, A.19
Ljung, B.M.20
Esserman, L.21
Albertson, D.G.22
Waldman, F.M.23
Gray, J.W.24
more..
-
20
-
-
84863115693
-
Subtype and pathway specific responses to anticancer compounds in breast cancer
-
L. M. Heiser, A. Sadanandam, W. L. Kuo, S. C. Benz, T. C. Goldstein, S. Ng, W. J. Gibb, N. J. Wang, S. Ziyad, F. Tong, N. Bayani, Z. Hu, J. I. Billig, A. Dueregger, S. Lewis, L. Jakkula, J. E. Korkola, S. Durinck, F. Pepin, Y. Guan, E. Purdom, P. Neuvial, H. Bengtsson, K. W. Wood, P. G. Smith, L. T. Vassilev, B. T. Hennessy, J. Greshock, K. E. Bachman, M. A. Hardwicke, J. W. Park, L. J. Marton, D. M. Wolf, E. A. Collisson, R. M. Neve, G. B. Mills, T. P. Speed, H. S. Feiler, R. F. Wooster, D. Haussler, J. M. Stuart, J. W. Gray, P. T. Spellman, Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 109, 2724-2729 (2012).
-
(2012)
Proc. Natl. Acad. Sci. U.S.A.
, vol.109
, pp. 2724-2729
-
-
Heiser, L.M.1
Sadanandam, A.2
Kuo, W.L.3
Benz, S.C.4
Goldstein, T.C.5
Ng, S.6
Gibb, W.J.7
Wang, N.J.8
Ziyad, S.9
Tong, F.10
Bayani, N.11
Hu, Z.12
Billig, J.I.13
Dueregger, A.14
Lewis, S.15
Jakkula, L.16
Korkola, J.E.17
Durinck, S.18
Pepin, F.19
Guan, Y.20
Purdom, E.21
Neuvial, P.22
Bengtsson, H.23
Wood, K.W.24
Smith, P.G.25
Vassilev, L.T.26
Hennessy, B.T.27
Greshock, J.28
Bachman, K.E.29
Hardwicke, M.A.30
Park, J.W.31
Marton, L.J.32
Wolf, D.M.33
Collisson, E.A.34
Neve, R.M.35
Mills, G.B.36
Speed, T.P.37
Feiler, H.S.38
Wooster, R.F.39
Haussler, D.40
Stuart, J.M.41
Gray, J.W.42
Spellman, P.T.43
more..
-
21
-
-
33845209913
-
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
-
R. M. Neve, K. Chin, J. Fridlyand, J. Yeh, F. L. Baehner, T. Fevr, L. Clark, N. Bayani, J. P. Coppe, F. Tong, T. Speed, P. T. Spellman, S. DeVries, A. Lapuk, N. J. Wang, W. L. Kuo, J. L. Stilwell, D. Pinkel, D. G. Albertson, F. M. Waldman, F. McCormick, R. B. Dickson, M. D. Johnson, M. Lippman, S. Ethier, A. Gazdar, J. W. Gray, A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
-
(2006)
Cancer Cell
, vol.10
, pp. 515-527
-
-
Neve, R.M.1
Chin, K.2
Fridlyand, J.3
Yeh, J.4
Baehner, F.L.5
Fevr, T.6
Clark, L.7
Bayani, N.8
Coppe, J.P.9
Tong, F.10
Speed, T.11
Spellman, P.T.12
DeVries, S.13
Lapuk, A.14
Wang, N.J.15
Kuo, W.L.16
Stilwell, J.L.17
Pinkel, D.18
Albertson, D.G.19
Waldman, F.M.20
McCormick, F.21
Dickson, R.B.22
Johnson, M.D.23
Lippman, M.24
Ethier, S.25
Gazdar, A.26
Gray, J.W.27
more..
-
22
-
-
84877028141
-
Comprehensive molecular portraits of human breast tumours
-
The Cancer Genome Atlas Network
-
The Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
-
(2012)
Nature
, vol.490
, pp. 61-70
-
-
-
23
-
-
84862526929
-
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
-
S. P. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha, Y. Zhao, G. Turashvili, J. Ding, K. Tse, G. Haffari, A. Bashashati, L. M. Prentice, J. Khattra, A. Burleigh, D. Yap, V. Bernard, A. McPherson, K. Shumansky, A. Crisan, R. Giuliany, A. Heravi-Moussavi, J. Rosner, D. Lai, I. Birol, R. Varhol, A. Tam, N. Dhalla, T. Zeng, K. Ma, S. K. Chan, M. Griffith, A. Moradian, S. W. G. Cheng, G. B. Morin, P. Watson, K. Gelmon, S. Chia, S.-F. Chin, C. Curtis, O. M. Rueda, P. D. Pharoah, S. Damaraju, J. Mackey, K. Hoon, T. Harkins, V. Tadigotla, M. Sigaroudinia, P. Gascard, T. Tlsty, J. F. Costello, I. M. Meyer, C. J. Eaves, W. W. Wasserman, S. Jones, D. Huntsman, M. Hirst, C. Caldas, M. A. Marra, S. Aparicio, The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012).
-
(2012)
Nature
, vol.486
, pp. 395-399
-
-
Shah, S.P.1
Roth, A.2
Goya, R.3
Oloumi, A.4
Ha, G.5
Zhao, Y.6
Turashvili, G.7
Ding, J.8
Tse, K.9
Haffari, G.10
Bashashati, A.11
Prentice, L.M.12
Khattra, J.13
Burleigh, A.14
Yap, D.15
Bernard, V.16
McPherson, A.17
Shumansky, K.18
Crisan, A.19
Giuliany, R.20
Heravi-Moussavi, A.21
Rosner, J.22
Lai, D.23
Birol, I.24
Varhol, R.25
Tam, A.26
Dhalla, N.27
Zeng, T.28
Ma, K.29
Chan, S.K.30
Griffith, M.31
Moradian, A.32
Cheng, S.W.G.33
Morin, G.B.34
Watson, P.35
Gelmon, K.36
Chia, S.37
Chin, S.-F.38
Curtis, C.39
Rueda, O.M.40
Pharoah, P.D.41
Damaraju, S.42
Mackey, J.43
Hoon, K.44
Harkins, T.45
Tadigotla, V.46
Sigaroudinia, M.47
Gascard, P.48
Tlsty, T.49
Costello, J.F.50
Meyer, I.M.51
Eaves, C.J.52
Wasserman, W.W.53
Jones, S.54
Huntsman, D.55
Hirst, M.56
Caldas, C.57
Marra, M.A.58
Aparicio, S.59
more..
-
24
-
-
84873089796
-
Updates in the treatment of basal/triple-negative breast cancer
-
M. Shastry, D. A. Yardley, Updates in the treatment of basal/triple-negative breast cancer. Curr. Opin. Obstet. Gynecol. 25, 40-48 (2013).
-
(2013)
Curr. Opin. Obstet. Gynecol.
, vol.25
, pp. 40-48
-
-
Shastry, M.1
Yardley, D.A.2
-
25
-
-
31144453233
-
BRAF mutation predicts sensitivity to MEK inhibition
-
D. B. Solit, L. A. Garraway, C. A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, J. M. Lobo, Y. She, I. Osman, T. R. Golub, J. Sebolt-Leopold, W. R. Sellers, N. Rosen, BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
-
(2006)
Nature
, vol.439
, pp. 358-362
-
-
Solit, D.B.1
Garraway, L.A.2
Pratilas, C.A.3
Sawai, A.4
Getz, G.5
Basso, A.6
Ye, Q.7
Lobo, J.M.8
She, Y.9
Osman, I.10
Golub, T.R.11
Sebolt-Leopold, J.12
Sellers, W.R.13
Rosen, N.14
-
26
-
-
84859169877
-
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
-
J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin, S. Kim, C. J. Wilson, J. Lehár, G. V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M. F. Berger, J. E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jané-Valbuena, F. A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I. H. Engels, J. Cheng, G. K. Yu, J. Yu, P. Aspesi Jr., M. de Silva, K. Jagtap, M. D. Jones, L. Wang, C. Hatton, E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R. C. Onofrio, T. Liefeld, L. MacConaill, W. Winckler, M. Reich, N. Li, J. P. Mesirov, S. B. Gabriel, G. Getz, K. Ardlie, V. Chan, V. E. Myer, B. L. Weber, J. Porter, M. Warmuth, P. Finan, J. L. Harris, M. Meyerson, T. R. Golub, M. P. Morrissey, W. R. Sellers, R. Schlegel, L. A. Garraway, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
-
(2012)
Nature
, vol.483
, pp. 603-607
-
-
Barretina, J.1
Caponigro, G.2
Stransky, N.3
Venkatesan, K.4
Margolin, A.A.5
Kim, S.6
Wilson, C.J.7
Lehár, J.8
Kryukov, G.V.9
Sonkin, D.10
Reddy, A.11
Liu, M.12
Murray, L.13
Berger, M.F.14
Monahan, J.E.15
Morais, P.16
Meltzer, J.17
Korejwa, A.18
Jané-Valbuena, J.19
Mapa, F.A.20
Thibault, J.21
Bric-Furlong, E.22
Raman, P.23
Shipway, A.24
Engels, I.H.25
Cheng, J.26
Yu, G.K.27
Yu, J.28
Aspesi Jr., P.29
De Silva, M.30
Jagtap, K.31
Jones, M.D.32
Wang, L.33
Hatton, C.34
Palescandolo, E.35
Gupta, S.36
Mahan, S.37
Sougnez, C.38
Onofrio, R.C.39
Liefeld, T.40
MacConaill, L.41
Winckler, W.42
Reich, M.43
Li, N.44
Mesirov, J.P.45
Gabriel, S.B.46
Getz, G.47
Ardlie, K.48
Chan, V.49
Myer, V.E.50
Weber, B.L.51
Porter, J.52
Warmuth, M.53
Finan, P.54
Harris, J.L.55
Meyerson, M.56
Golub, T.R.57
Morrissey, M.P.58
Sellers, W.R.59
Schlegel, R.60
Garraway, L.A.61
more..
-
27
-
-
84859187259
-
Systematic identification of genomic markers of drug sensitivity in cancer cells
-
M. J. Garnett, E. J. Edelman, S. J. Heidorn, C. D. Greenman, A. Dastur, K. W. Lau, P. Greninger, I. R. Thompson, X. Luo, J. Soares, Q. Liu, F. Iorio, D. Surdez, L. Chen, R. J. Milano, G. R. Bignell, A. T. Tam, H. Davies, J. A. Stevenson, S. Barthorpe, S. R. Lutz, F. Kogera, K. Lawrence, A. McLaren-Douglas, X. Mitropoulos, T. Mironenko, H. Thi, L. Richardson, W. Zhou, F. Jewitt, T. Zhang, P. O'Brien, J. L. Boisvert, S. Price, W. Hur, W. Yang, X. Deng, A. Butler, H. G. Choi, J. W. Chang, J. Baselga, I. Stamenkovic, J. A. Engelman, S. V. Sharma, O. Delattre, J. Saez-Rodriguez, N. S. Gray, J. Settleman, P. A. Futreal, D. A. Haber, M. R. Stratton, S. Ramaswamy, U. McDermott, C. H. Benes, Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
-
(2012)
Nature
, vol.483
, pp. 570-575
-
-
Garnett, M.J.1
Edelman, E.J.2
Heidorn, S.J.3
Greenman, C.D.4
Dastur, A.5
Lau, K.W.6
Greninger, P.7
Thompson, I.R.8
Luo, X.9
Soares, J.10
Liu, Q.11
Iorio, F.12
Surdez, D.13
Chen, L.14
Milano, R.J.15
Bignell, G.R.16
Tam, A.T.17
Davies, H.18
Stevenson, J.A.19
Barthorpe, S.20
Lutz, S.R.21
Kogera, F.22
Lawrence, K.23
McLaren-Douglas, A.24
Mitropoulos, X.25
Mironenko, T.26
Thi, H.27
Richardson, L.28
Zhou, W.29
Jewitt, F.30
Zhang, T.31
O'Brien, P.32
Boisvert, J.L.33
Price, S.34
Hur, W.35
Yang, W.36
Deng, X.37
Butler, A.38
Choi, H.G.39
Chang, J.W.40
Baselga, J.41
Stamenkovic, I.42
Engelman, J.A.43
Sharma, S.V.44
Delattre, O.45
Saez-Rodriguez, J.46
Gray, N.S.47
Settleman, J.48
Futreal, P.A.49
Haber, D.A.50
Stratton, M.R.51
Ramaswamy, S.52
McDermott, U.53
Benes, C.H.54
more..
-
28
-
-
84863258395
-
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors
-
F. Meric-Bernstam, A. Akcakanat, H. Chen, K. A. Do, T. Sangai, F. Adkins, A. M. Gonzalez-Angulo, A. Rashid, K. Crosby, M. Dong, A. T. Phan, R. A. Wolff, S. Gupta, G. B. Mills, J. Yao, PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin. Cancer Res. 18, 1777-1789 (2012).
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 1777-1789
-
-
Meric-Bernstam, F.1
Akcakanat, A.2
Chen, H.3
Do, K.A.4
Sangai, T.5
Adkins, F.6
Gonzalez-Angulo, A.M.7
Rashid, A.8
Crosby, K.9
Dong, M.10
Phan, A.T.11
Wolff, R.A.12
Gupta, S.13
Mills, G.B.14
Yao, J.15
-
29
-
-
84860851412
-
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks
-
M. J. Lee, A. S. Ye, A. K. Gardino, A. M. Heijink, P. K. Sorger, G. MacBeath, M. B. Yaffe, Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
-
(2012)
Cell
, vol.149
, pp. 780-794
-
-
Lee, M.J.1
Ye, A.S.2
Gardino, A.K.3
Heijink, A.M.4
Sorger, P.K.5
MacBeath, G.6
Yaffe, M.B.7
-
30
-
-
58349091262
-
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
-
O. K. Mirzoeva, D. Das, L. M. Heiser, S. Bhattacharya, D. Siwak, R. Gendelman, N. Bayani, N. J. Wang, R. M. Neve, Y. Guan, Z. Hu, Z. Knight, H. S. Feiler, P. Gascard, B. Parvin, P. T. Spellman, K. M. Shokat, A. J. Wyrobek, M. J. Bissell, F. McCormick, W. L. Kuo, G. B. Mills, J. W. Gray, W. M. Korn, Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69, 565-572 (2009).
-
(2009)
Cancer Res.
, vol.69
, pp. 565-572
-
-
Mirzoeva, O.K.1
Das, D.2
Heiser, L.M.3
Bhattacharya, S.4
Siwak, D.5
Gendelman, R.6
Bayani, N.7
Wang, N.J.8
Neve, R.M.9
Guan, Y.10
Hu, Z.11
Knight, Z.12
Feiler, H.S.13
Gascard, P.14
Parvin, B.15
Spellman, P.T.16
Shokat, K.M.17
Wyrobek, A.J.18
Bissell, M.J.19
McCormick, F.20
Kuo, W.L.21
Mills, G.B.22
Gray, J.W.23
Korn, W.M.24
more..
-
31
-
-
84866096861
-
Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators
-
B. Bodenmiller, E. R. Zunder, R. Finck, T. J. Chen, E. S. Savig, R. V. Bruggner, E. F. Simonds, S. C. Bendall, K. Sachs, P. O. Krutzik, G. P. Nolan, Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat. Biotechnol. 30, 858-867 (2012).
-
(2012)
Nat. Biotechnol.
, vol.30
, pp. 858-867
-
-
Bodenmiller, B.1
Zunder, E.R.2
Finck, R.3
Chen, T.J.4
Savig, E.S.5
Bruggner, R.V.6
Simonds, E.F.7
Bendall, S.C.8
Sachs, K.9
Krutzik, P.O.10
Nolan, G.P.11
-
32
-
-
84864286442
-
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
-
T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y. Wang, J. Sosman, A. Ribas, J. Li, J. Moffat, D. P. Sutherlin, H. Koeppen, M. Merchant, R. Neve, J. Settleman, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
-
(2012)
Nature
, vol.487
, pp. 505-509
-
-
Wilson, T.R.1
Fridlyand, J.2
Yan, Y.3
Penuel, E.4
Burton, L.5
Chan, E.6
Peng, J.7
Lin, E.8
Wang, Y.9
Sosman, J.10
Ribas, A.11
Li, J.12
Moffat, J.13
Sutherlin, D.P.14
Koeppen, H.15
Merchant, M.16
Neve, R.17
Settleman, J.18
-
33
-
-
84864285794
-
Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion
-
R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, M. M. Mongare, J. Gould, D. T. Frederick, Z. A. Cooper, P. B. Chapman, D. B. Solit, A. Ribas, R. S. Lo, K. T. Flaherty, S. Ogino, J. A. Wargo, T. R. Golub, Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
-
(2012)
Nature
, vol.487
, pp. 500-504
-
-
Straussman, R.1
Morikawa, T.2
Shee, K.3
Barzily-Rokni, M.4
Qian, Z.R.5
Du, J.6
Davis, A.7
Mongare, M.M.8
Gould, J.9
Frederick, D.T.10
Cooper, Z.A.11
Chapman, P.B.12
Solit, D.B.13
Ribas, A.14
Lo, R.S.15
Flaherty, K.T.16
Ogino, S.17
Wargo, J.A.18
Golub, T.R.19
-
34
-
-
0033304746
-
erbB-2 overexpression in human mammary epithelial cells confers growth factor independence
-
K. M. Ignatoski, A. J. Lapointe, E. H. Radany, S. P. Ethier, erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology 140, 3615-3622 (1999).
-
(1999)
Endocrinology
, vol.140
, pp. 3615-3622
-
-
Ignatoski, K.M.1
Lapointe, A.J.2
Radany, E.H.3
Ethier, S.P.4
-
35
-
-
0031010495
-
Secondary dimerization between members of the epidermal growth factor receptor family
-
D. C. Gamett, G. Pearson, R. A. Cerione, I. Friedberg, Secondary dimerization between members of the epidermal growth factor receptor family. J. Biol. Chem. 272, 12052-12056 (1997).
-
(1997)
J. Biol. Chem.
, vol.272
, pp. 12052-12056
-
-
Gamett, D.C.1
Pearson, G.2
Cerione, R.A.3
Friedberg, I.4
-
36
-
-
28244432561
-
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
-
R. Nahta, L. X. Yuan, B. Zhang, R. Kobayashi, F. J. Esteva, Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65, 11118-11128 (2005).
-
(2005)
Cancer Res.
, vol.65
, pp. 11118-11128
-
-
Nahta, R.1
Yuan, L.X.2
Zhang, B.3
Kobayashi, R.4
Esteva, F.J.5
-
37
-
-
57749089652
-
Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival
-
J. H. Law, G. Habibi, K. Hu, H. Masoudi, M. Y. Wang, A. L. Stratford, E. Park, J. M. Gee, P. Finlay, H. E. Jones, R. I. Nicholson, J. Carboni, M. Gottardis, M. Pollak, S. E. Dunn, Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68, 10238-10246 (2008).
-
(2008)
Cancer Res.
, vol.68
, pp. 10238-10246
-
-
Law, J.H.1
Habibi, G.2
Hu, K.3
Masoudi, H.4
Wang, M.Y.5
Stratford, A.L.6
Park, E.7
Gee, J.M.8
Finlay, P.9
Jones, H.E.10
Nicholson, R.I.11
Carboni, J.12
Gottardis, M.13
Pollak, M.14
Dunn, S.E.15
-
38
-
-
77950974697
-
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors
-
R. Kurzrock, A. Patnaik, J. Aisner, T. Warren, S. Leong, R. Benjamin, S. G. Eckhardt, J. E. Eid, G. Greig, K. Habben, C. D. McCarthy, L. Gore, A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin. Cancer Res. 16, 2458-2465 (2010).
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 2458-2465
-
-
Kurzrock, R.1
Patnaik, A.2
Aisner, J.3
Warren, T.4
Leong, S.5
Benjamin, R.6
Eckhardt, S.G.7
Eid, J.E.8
Greig, G.9
Habben, K.10
McCarthy, C.D.11
Gore, L.12
-
39
-
-
83355174075
-
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
-
S. S. Ramalingam, D. R. Spigel, D. Chen, M. B. Steins, J. A. Engelman, C. P. Schneider, S. Novello, W. E. Eberhardt, L. Crino, K. Habben, L. Liu, P. A. Jänne, C. M. Brownstein, M. Reck, Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 29, 4574-4580 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 4574-4580
-
-
Ramalingam, S.S.1
Spigel, D.R.2
Chen, D.3
Steins, M.B.4
Engelman, J.A.5
Schneider, C.P.6
Novello, S.7
Eberhardt, W.E.8
Crino, L.9
Habben, K.10
Liu, L.11
Jänne, P.A.12
Brownstein, C.M.13
Reck, M.14
-
40
-
-
84859873169
-
cMET and phospho-cMET protein levels in breast cancers and survival outcomes
-
K. P. Raghav, W. Wang, S. Liu, M. Chavez-MacGregor, X. Meng, G. N. Hortobagyi, G. B. Mills, F. Meric-Bernstam, G. R. Blumenschein Jr., A. M. Gonzalez-Angulo, cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin. Cancer Res. 18, 2269-2277 (2012).
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 2269-2277
-
-
Raghav, K.P.1
Wang, W.2
Liu, S.3
Chavez-MacGregor, M.4
Meng, X.5
Hortobagyi, G.N.6
Mills, G.B.7
Meric-Bernstam, F.8
Blumenschein Jr., G.R.9
Gonzalez-Angulo, A.M.10
-
41
-
-
44449151030
-
Drug development of MET inhibitors: Targeting oncogene addiction and expedience
-
P. M. Comoglio, S. Giordano, L. Trusolino, Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7, 504-516 (2008).
-
(2008)
Nat. Rev. Drug Discov.
, vol.7
, pp. 504-516
-
-
Comoglio, P.M.1
Giordano, S.2
Trusolino, L.3
-
42
-
-
84859415553
-
Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer
-
A. N. Brooks, E. Kilgour, P. D. Smith, Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer. Clin. Cancer Res. 18, 1855-1862 (2012).
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 1855-1862
-
-
Brooks, A.N.1
Kilgour, E.2
Smith, P.D.3
-
43
-
-
0037591513
-
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
-
T. Bachelot, I. Ray-Coquard, C. Menetrier-Caux, M. Rastkha, A. Duc, J. Y. Blay, Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer 88, 1721-1726 (2003).
-
(2003)
Br. J. Cancer
, vol.88
, pp. 1721-1726
-
-
Bachelot, T.1
Ray-Coquard, I.2
Menetrier-Caux, C.3
Rastkha, M.4
Duc, A.5
Blay, J.Y.6
-
44
-
-
0037455841
-
Circulating interleukin-6 predicts survival in patients with metastatic breast cancer
-
R. Salgado, S. Junius, I. Benoy, P. Van Dam, P. Vermeulen, E. Van Marck, P. Huget, L. Y. Dirix, Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer 103, 642-646 (2003).
-
(2003)
Int. J. Cancer
, vol.103
, pp. 642-646
-
-
Salgado, R.1
Junius, S.2
Benoy, I.3
Van Dam, P.4
Vermeulen, P.5
Van Marck, E.6
Huget, P.7
Dirix, L.Y.8
-
45
-
-
0033036097
-
Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma
-
G. J. Zhang, I. Adachi, Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19, 1427-1432 (1999).
-
(1999)
Anticancer Res.
, vol.19
, pp. 1427-1432
-
-
Zhang, G.J.1
Adachi, I.2
-
46
-
-
40449113978
-
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
-
D. L. Shattuck, J. K. Miller, K. L. Carraway III, C. Sweeney, Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68, 1471-1477 (2008).
-
(2008)
Cancer Res.
, vol.68
, pp. 1471-1477
-
-
Shattuck, D.L.1
Miller, J.K.2
Carraway III, K.L.3
Sweeney, C.4
-
47
-
-
84885815639
-
-
ClinicalTrials.gov accessed 28 August 2013
-
ClinicalTrials.gov, http://clinicaltrials.gov [accessed 28 August 2013].
-
-
-
-
48
-
-
84875554160
-
Genomic determinants of PI3K pathway inhibitor response in cancer
-
B. Weigelt, J. Downward, Genomic determinants of PI3K pathway inhibitor response in cancer. Front. Oncol. 2, 109 (2012).
-
(2012)
Front. Oncol.
, vol.2
, pp. 109
-
-
Weigelt, B.1
Downward, J.2
-
49
-
-
84857236823
-
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial
-
on behalf of the NeoALTTO Study Team
-
J. Baselga, I. Bradbury, H. Eidtmann, S. Di Cosimo, E. de Azambuja, C. Aura, H. Gómez, P. Dinh, K. Fauria, V. Van Dooren, G. Aktan, A. Goldhirsch, T. W. Chang, Z. Horvath, M. Coccia-Portugal, J. Domont, L. M. Tseng, G. Kunz, J. H. Sohn, V. Semiglazov, G. Lerzo, M. Palacova, V. Probachai, L. Pusztai, M. Untch, R. D. Gelber, M. Piccart-Gebhart, on behalf of the NeoALTTO Study Team, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379, 633-640 (2012).
-
(2012)
Lancet
, vol.379
, pp. 633-640
-
-
Baselga, J.1
Bradbury, I.2
Eidtmann, H.3
Di Cosimo, S.4
De Azambuja, E.5
Aura, C.6
Gómez, H.7
Dinh, P.8
Fauria, K.9
Van Dooren, V.10
Aktan, G.11
Goldhirsch, A.12
Chang, T.W.13
Horvath, Z.14
Coccia-Portugal, M.15
Domont, J.16
Tseng, L.M.17
Kunz, G.18
Sohn, J.H.19
Semiglazov, V.20
Lerzo, G.21
Palacova, M.22
Probachai, V.23
Pusztai, L.24
Untch, M.25
Gelber, R.D.26
Piccart-Gebhart, M.27
more..
-
50
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein, D. Cameron, Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006).
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
Jagiello-Gruszfeld, A.7
Crown, J.8
Chan, A.9
Kaufman, B.10
Skarlos, D.11
Campone, M.12
Davidson, N.13
Berger, M.14
Oliva, C.15
Rubin, S.D.16
Stein, S.17
Cameron, D.18
-
51
-
-
63449138706
-
Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation
-
A. Roidl, H. J. Berger, S. Kumar, J. Bange, P. Knyazev, A. Ullrich, Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin. Cancer Res. 15, 2058-2066 (2009).
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 2058-2066
-
-
Roidl, A.1
Berger, H.J.2
Kumar, S.3
Bange, J.4
Knyazev, P.5
Ullrich, A.6
-
52
-
-
84882986288
-
Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma
-
M. Moschetta, A. Basile, A. Ferrucci, M. A. Frassanito, L. Rao, R. Ria, A. G. Solimando, N. Giuliani, A. Boccarelli, F. Fumarola, M. Coluccia, B. Rossini, S. Ruggieri, B. Nico, E. Maiorano, D. Ribatti, A. M. Roccaro, A. Vacca, Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clin. Cancer Res. 19, 4371-4382 (2013).
-
(2013)
Clin. Cancer Res.
, vol.19
, pp. 4371-4382
-
-
Moschetta, M.1
Basile, A.2
Ferrucci, A.3
Frassanito, M.A.4
Rao, L.5
Ria, R.6
Solimando, A.G.7
Giuliani, N.8
Boccarelli, A.9
Fumarola, F.10
Coluccia, M.11
Rossini, B.12
Ruggieri, S.13
Nico, B.14
Maiorano, E.15
Ribatti, D.16
Roccaro, A.M.17
Vacca, A.18
-
53
-
-
84865401715
-
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population
-
H. Korkaya, G. I. Kim, A. Davis, F. Malik, N. L. Henry, S. Ithimakin, A. A. Quraishi, N. Tawakkol, R. D'Angelo, A. K. Paulson, S. Chung, T. Luther, H. J. Paholak, S. Liu, K. A. Hassan, Q. Zen, S. G. Clouthier, M. S. Wicha, Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 47, 570-584 (2012).
-
(2012)
Mol. Cell
, vol.47
, pp. 570-584
-
-
Korkaya, H.1
Kim, G.I.2
Davis, A.3
Malik, F.4
Henry, N.L.5
Ithimakin, S.6
Quraishi, A.A.7
Tawakkol, N.8
D'Angelo, R.9
Paulson, A.K.10
Chung, S.11
Luther, T.12
Paholak, H.J.13
Liu, S.14
Hassan, K.A.15
Zen, Q.16
Clouthier, S.G.17
Wicha, M.S.18
-
54
-
-
84874787799
-
Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial
-
D. C. Smith, M. R. Smith, C. Sweeney, A. A. Elfiky, C. Logothetis, P. G. Corn, N. J. Vogelzang, E. J. Small, A. L. Harzstark, M. S. Gordon, U. N. Vaishampayan, N. B. Haas, A. I. Spira, P. N. Lara Jr., C. C. Lin, S. Srinivas, A. Sella, P. Schöffski, C. Scheffold, A. L. Weitzman, M. Hussain, Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J. Clin. Oncol. 31, 412-419 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 412-419
-
-
Smith, D.C.1
Smith, M.R.2
Sweeney, C.3
Elfiky, A.A.4
Logothetis, C.5
Corn, P.G.6
Vogelzang, N.J.7
Small, E.J.8
Harzstark, A.L.9
Gordon, M.S.10
Vaishampayan, U.N.11
Haas, N.B.12
Spira, A.I.13
Lara Jr., P.N.14
Lin, C.C.15
Srinivas, S.16
Sella, A.17
Schöffski, P.18
Scheffold, C.19
Weitzman, A.L.20
Hussain, M.21
more..
-
55
-
-
84872548337
-
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
-
T. K. Choueiri, U. Vaishampayan, J. E. Rosenberg, T. F. Logan, A. L. Harzstark, R. M. Bukowski, B. I. Rini, S. Srinivas, M. N. Stein, L. M. Adams, L. H. Ottesen, K. H. Laubscher, L. Sherman, D. F. McDermott, N. B. Haas, K. T. Flaherty, R. Ross, P. Eisenberg, P. S. Meltzer, M. J. Merino, D. P. Bottaro, W. M. Linehan, R. Srinivasan, Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol. 31, 181-186 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 181-186
-
-
Choueiri, T.K.1
Vaishampayan, U.2
Rosenberg, J.E.3
Logan, T.F.4
Harzstark, A.L.5
Bukowski, R.M.6
Rini, B.I.7
Srinivas, S.8
Stein, M.N.9
Adams, L.M.10
Ottesen, L.H.11
Laubscher, K.H.12
Sherman, L.13
McDermott, D.F.14
Haas, N.B.15
Flaherty, K.T.16
Ross, R.17
Eisenberg, P.18
Meltzer, P.S.19
Merino, M.J.20
Bottaro, D.P.21
Linehan, W.M.22
Srinivasan, R.23
more..
-
56
-
-
84866171951
-
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
-
D. M. French, B. C. Lin, M. Wang, C. Adams, T. Shek, K. Hötzel, B. Bolon, R. Ferrando, C. Blackmore, K. Schroeder, L. A. Rodriguez, M. Hristopoulos, R. Venook, A. Ashkenazi, L. R. Desnoyers, Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 7, e36713 (2012).
-
(2012)
PLoS One
, vol.7
-
-
French, D.M.1
Lin, B.C.2
Wang, M.3
Adams, C.4
Shek, T.5
Hötzel, K.6
Bolon, B.7
Ferrando, R.8
Blackmore, C.9
Schroeder, K.10
Rodriguez, L.A.11
Hristopoulos, M.12
Venook, R.13
Ashkenazi, A.14
Desnoyers, L.R.15
-
57
-
-
0027502201
-
Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth
-
K. Sato, M. Tsuchiya, J. Saldanha, Y. Koishihara, Y. Ohsugi, T. Kishimoto, M. M. Bendig, Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 53, 851-856 (1993).
-
(1993)
Cancer Res.
, vol.53
, pp. 851-856
-
-
Sato, K.1
Tsuchiya, M.2
Saldanha, J.3
Koishihara, Y.4
Ohsugi, Y.5
Kishimoto, T.6
Bendig, M.M.7
-
58
-
-
84876196796
-
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
-
P. M. Voorhees, R. F. Manges, P. Sonneveld, S. Jagannath, G. Somlo, A. Krishnan, S. Lentzsch, R. C. Frank, S. Zweegman, P. W. Wijermans, R. Z. Orlowski, B. Kranenburg, B. Hall, T. Casneuf, X. Qin, H. van de Velde, H. Xie, S. K. Thomas, A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 161, 357-366 (2013).
-
(2013)
Br. J. Haematol.
, vol.161
, pp. 357-366
-
-
Voorhees, P.M.1
Manges, R.F.2
Sonneveld, P.3
Jagannath, S.4
Somlo, G.5
Krishnan, A.6
Lentzsch, S.7
Frank, R.C.8
Zweegman, S.9
Wijermans, P.W.10
Orlowski, R.Z.11
Kranenburg, B.12
Hall, B.13
Casneuf, T.14
Qin, X.15
Van De Velde, H.16
Xie, H.17
Thomas, S.K.18
-
59
-
-
36549089022
-
Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
-
I. R. Hutcheson, J. M. Knowlden, S. E. Hiscox, D. Barrow, J. M. Gee, J. F. Robertson, I. O. Ellis, R. I. Nicholson, Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res. 9, R50 (2007).
-
(2007)
Breast Cancer Res.
, vol.9
-
-
Hutcheson, I.R.1
Knowlden, J.M.2
Hiscox, S.E.3
Barrow, D.4
Gee, J.M.5
Robertson, J.F.6
Ellis, I.O.7
Nicholson, R.I.8
-
60
-
-
84885049277
-
Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110a inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers
-
10.1158/0008-5472.CAN-13-1191
-
J. T. Garrett, C. R. Sutton, R. Kurupi, C. U. Bialucha, S. A. Ettenberg, S. D. Collins, Q. Sheng, J. Wallweber, L. Defazio-Eli, C. L. Arteaga, Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110a inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res. 10.1158/0008-5472.CAN-13-1191 (2013).
-
(2013)
Cancer Res.
-
-
Garrett, J.T.1
Sutton, C.R.2
Kurupi, R.3
Bialucha, C.U.4
Ettenberg, S.A.5
Collins, S.D.6
Sheng, Q.7
Wallweber, J.8
Defazio-Eli, L.9
Arteaga, C.L.10
-
61
-
-
79957839340
-
Adaptive informatics for multifactorial and high-content biological data
-
B. L. Millard, M. Niepel, M. P. Menden, J. L. Muhlich, P. K. Sorger, Adaptive informatics for multifactorial and high-content biological data. Nat. Methods 8, 487-493 (2011).
-
(2011)
Nat. Methods
, vol.8
, pp. 487-493
-
-
Millard, B.L.1
Niepel, M.2
Menden, M.P.3
Muhlich, J.L.4
Sorger, P.K.5
-
62
-
-
0038620211
-
Prediction of clinical outcome with microarray data: A partial least squares discriminant analysis (PLS-DA) approach
-
M. Pérez-Enciso, M. Tenenhaus, Prediction of clinical outcome with microarray data: A partial least squares discriminant analysis (PLS-DA) approach. Hum. Genet. 112, 581-592 (2003).
-
(2003)
Hum. Genet.
, vol.112
, pp. 581-592
-
-
Pérez-Enciso, M.1
Tenenhaus, M.2
-
63
-
-
84885810103
-
-
Morgan Kaufmann Publishers, Burlington, MA, ed. 3, chap. 5.3
-
I. H. Witten, E. Frank, M. A. Hall, Data Mining (Morgan Kaufmann Publishers, Burlington, MA, ed. 3, 2011), chap. 5.3.
-
(2011)
Data Mining
-
-
Witten, I.H.1
Frank, E.2
Hall, M.A.3
-
64
-
-
33644860703
-
Bias in error estimation when using cross-validation for model selection
-
A. Varma, R. Simon, Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics 7, 91 (2006).
-
(2006)
BMC Bioinformatics
, vol.7
, pp. 91
-
-
Varma, A.1
Simon, R.2
|